ClinicalTrials.gg
CompletedNCT01020526Updated Jan 28, 2021Results posted

Pregabalin In Adolescent Patients With Fibromyalgia

A Phase 4 interventional study of pregabalin in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 26 sites in 3 countries. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.

Enrollment
24th of 30
63 · median 199
Started
2010
with 2 others
Phase 4
7 of 30
none open now
Registered
12th of 30
by date
Lead sponsor
15 of 30
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 24th largest by enrollment, is one of 3 that started in 2010, is one of 7 in phase 4, and was the 12th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pregabalin in Fibromyalgia, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the long-term safety of pregabalin in adolescent patients who participated in the previous fibromyalgia study (A0081180) and who wish to recieve open-label pregabalin

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have met the inclusion criteria for the preceding fibromyalgia Study A0081180, and have received pregabalin/placebo under double-blind conditions.

Exclusion criteria

Exclusion Criteria:

  • Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia study A0081180 which was determined to be related to the study medication by the investigator or sponsor.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Drug: pregabalin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pain Numeric Rating Scale by Week

    The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain. Participants chose the number that best described the pain during the last week. Negative change indicates improvement.

    Time frame: Baseline, Weeks 3, 8, 16, 24 and Last Visit.

07

Results

Posted Jul 1, 2016

Participant flow

A total of 63 participants were screened and enrolled at 19 study centers in this open-label extension study to the parent double-blind randomized fibromyalgia study A0081180.

Participant flow — Overall Study
MilestonePregabalin
Started63
Completed49
Not completed14
Withdrew: Withdrawal by subject5
Withdrew: Other reasons3
Withdrew: Insufficient clinical response3
Withdrew: Lost to follow-up1
Withdrew: Adverse event2

Outcome measures

PrimaryChange From Baseline in Pain Numeric Rating Scale by Week

The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain. Participants chose the number that best described the pain during the last week. Negative change indicates improvement.

Time frame:
Baseline, Weeks 3, 8, 16, 24 and Last Visit.
Reported as:
Mean · Number
Change From Baseline in Pain Numeric Rating Scale by Week
NumberPregabalin
Baseline (N=63)6.7 ± 1.68
Week 3 (N=61)-2.1 ± 2.51
Week 8 (N=55)-1.8 ± 2.95
Week 16 (N=51)-2.1 ± 2.6
Week 24 (N=55)-2.1 ± 2.56
Last Visit (N=63)-2.1 ± 2.47

Adverse events

Collected over Adverse Events were recorded from the time the participants had taken at least one dose of study drug through the last subject visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—3/63 (4.8%)32/63 (50.8%)
Most frequent serious events
Most frequent serious events
EventPregabalin
AppendicitisInfections and infestations1/63
Joint instabilityMusculoskeletal and connective tissue disorders1/63
MigraineNervous system disorders1/63
Most frequent other events
Most frequent other events
EventPregabalin
DizzinessNervous system disorders14/63
FatigueGeneral disorders8/63
HeadacheNervous system disorders6/63
Abdominal painGastrointestinal disorders5/63
Abdominal pain upperGastrointestinal disorders5/63
NauseaGastrointestinal disorders5/63
Ear infectionInfections and infestations4/63
Upper respiratory tract infectionInfections and infestations4/63
Nasal congestionRespiratory, thoracic and mediastinal disorders4/63
DysmenorrhoeaReproductive system and breast disorders3/53

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pregabalin
Mean14.8 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female53
Male10
08

Study locations

26 sites
  • Childrens Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Apex Research Institute
    Santa Ana, California 92705, United States
  • Florida Medical Center & Research
    Miami, Florida 33142, United States
  • Harmony Clinical Research, Incorporated
    North Miami Beach, Florida 33162, United States
  • Rheumatology Associates of Central Florida, PA
    Orlando, Florida 32806, United States
  • Medical Research & Health Education Foundation, Inc.
    Columbus, Georgia 31909, United States
  • Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • Kosair Children's Hospital
    Louisville, Kentucky 40202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • University Pediatric Rheumatology of Kentucky, LLC
    Louisville, Kentucky 40202, United States
  • University of Massachusetts Memorial Medical Center Department of Pediatrics
    Worcester, Massachusetts 01655, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Akron Children's Hospital-Mahoning Valley
    Boardman, Ohio 44512, United States
  • Akron Children's Hospital
    Boardman, Ohio 44512, United States
  • University of Cincinnati Department of Psychiatry and Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • The Research Institute at Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Medical University of South Carolina, Pediatric Rheumatology
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Carolina Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Fatigue Consultation Clinic
    Salt Lake City, Utah 84102, United States
  • Bioregeneracni a rehabilitacni centrum
    Ricany, 25101, Czechia
  • Krishna Institute of Medical Sciences Ltd
    Secunderabad, Andhra Pradesh 500 003, India
  • Mallikatta Neuro Center
    Mangalore, Karnataka 575002, India
  • Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics
    Nagpur, Maharashtra 440010, India
  • King George's Medical University
    Lucknow, Uttar Pradesh 226 018, India
09

References and documents

Publications

  • Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, Bhadra-Brown P, Clair A, Chew ML, Scavone J; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016 Jul 30;14(1):46. doi: 10.1186/s12969-016-0106-4. PubMed 27475753 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2009
First posted
Nov 25, 2009
Start
Sep 2010
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Jul 1, 2016
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01020526
Responsible party
Sponsor
First posted
Nov 25, 2009
Start date
Sep 2010
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Jul 1, 2016
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion